Application of Small-Angle X-ray Scattering (SAXS) to Pharmaceuticals

Small-angle X-ray scattering (SAXS) offers various ways to characterize pharmaceutical formulations, drug carrier systems, vaccines, and active pharmaceutical ingredients (APIs) as well as viruses of various kinds. The SAXS method can determine the size, shape, internal structure, and morphology as well as interactions of such materials and therefore contributes to a better understanding of their functionality. In addition to classical SAXS analysis, scattering information at wider scattering angles (WAXS) as well as GISAXS analysis of pharmaceutical thin-film samples expand the possibilities of fundamental research, development and production/quality control of pharmaceuticals.

Today, the aforementioned investigations and studies can be performed on advanced laboratory SAXS/WAXS/GISAXS instrumentation. In this webinar we will discuss selected examples of SAXS/WAXS/GISAXS scattering studies on pharmaceutical materials and highlight the results and findings which are obtained by X-ray scattering.

The webinar content will be:

  • Introduction to the SAXS/WAXS/GISAXS method with respect to pharmaceuticals
  • Discussion of selected application examples of X-ray scattering studies on pharmaceuticals

Target group:

  • Anyone interested in the structural characterization of pharmaceuticals in the home laboratory
  • Anyone using complementary techniques (e.g. SC-XRD, Cryo-EM, NMR, etc.) for analyzing pharmaceutical materials
  • Anyone working in research and development as well as production and QC of pharmaceutical materials


Dr. Andreas Keilbach (English)
Dr. Andreas Keilbach (English)
Andreas Keilbach

Dr. Andreas Keilbach obtained his PhD in Physical Chemistry from the University of Munich, with a focus in porous materials. After his PhD studies, he joined Anton Paar in April 2011 and is currently part product manager for small-angle X-ray scattering at Anton Paar GmbH.

Get free access now!

Simply fill out the form below to receive free access to tools and restricted content.